Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3121940 | 0.96 | SLC6A4 (0.58) | SLC6A3SLC6A4SLC6A2MAOAMAOB | |
| SCHEMBL1041125 | 0.91 | SLC6A4 (0.52) | SLC6A3SLC6A4SLC6A2HDAC4MAOA | |
| SCHEMBL5873448 | 0.79 | SLC6A4 (0.63) | SLC6A3SLC6A4SLC6A2HDAC4 | |
| SCHEMBL7888175 | 0.79 | SLC6A3 (0.96) | SLC6A3SLC6A4SLC6A2DPP4 | |
| SCHEMBL3890243 | 0.78 | DPP4 (0.63) | SLC6A3SLC6A4SLC6A2MAOAMAOB | |
| SCHEMBL3663025 | 0.78 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2DPP4 | |
| SCHEMBL28438976 | 0.78 | SLC6A4 (0.67) | SLC6A3SLC6A4SLC6A2HDAC4 | |
| SCHEMBL31441154 | 0.78 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2DPP4 | |
| Hydrochloric Acid SCHEMBL3523556 | 0.76 | SLC6A3 (0.96) | SLC6A3SLC6A4SLC6A2DPP4 | |
| SCHEMBL15043618 | 0.76 | SLC6A4 (0.59) | SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498344-B2 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| EP-0755923-B1 | Ameliorant or remedy for symptoms caused by Ischemic diseases and Phenylpiperidine compounds useful therefor | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2005-05-04 | — | — | EP | disclosed |
| EP-0867183-B1 | ARYLPIPERIDINOL AND ARYLPIPERIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-20040186138-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | DAIICHI SUNTORY PHARMA CO., LTD. | 2004-09-23 | — | — | US | disclosed |
| US-6706734-B2 | ANTIISCHEMIC AGENTS; ANTICONVULSANTS; HEADACHES | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-16 | — | — | US | disclosed |
| US-20030130312-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2003-07-10 | — | — | US | disclosed |
| US-6469010-B1 | COMPOSITION ALSO FOR ALLEVIATION OR TREATMENT OF SYMPTOMS DERIVED FROM SEIZURES, EPILEPSY AND MIGRAINE HEADACHES, AND SUPPRESSION OF CALCIUM ION OVERLOAD | SUNTORY LIMITED (JP) | 2002-10-22 | — | — | US | disclosed |
| US-6455549-B1 | ANTIEPILEPTIC, ANTIISCHEMIC, AND ANTIMIGRAINE AGENTS; CALCIUM OVELOAD SUPPRESSANTS | SUNTORY LIMITED (JP) | 2002-09-24 | — | — | US | disclosed |
| US-6048876-A | ANTICONVULSANTS; ANTIEPILEPIC AGENT | SUNTORY LIMITED (JP) | 2000-04-11 | — | — | US | disclosed |
| EP-0867183-A1 | ARYLPIPERIDINOL AND ARYLPIPERIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1998-09-30 | — | — | EP | disclosed |
| EP-0755923-A1 | AMELIORANT OR REMEDY FOR SYMPTOMS CAUSED BY ISCHEMIC DISEASES AND COMPOUNDS USEFUL THEREFOR | SUNTORY LIMITED (JP) | 1997-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130312-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | KCNH1, KCNH2, NPY1R | SLC6A3 3526/4885SLC6A4 1503/4885SLC6A2 2045/4885 |
| US-20040186138-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | KCNH1, KCNH2, NPY1R | SLC6A3 3526/4885SLC6A4 1503/4885SLC6A2 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.